OBJECTIVES: To establish a rational ritodrine therapy in relation to serum ritodrine concentration, we examined 14 twin pregnancy patients and determined their pharmacokinetic data. METHODS: We measured serum concentrations of ritodrine in twin pregnancy patients using high-performance liquid chromatography (HPLC). RESULTS: The twin pregnancy patients all exhibited linear ritodrine pharmacokinetic profiles. There was a statistically significant but slight negative correlation between gestation period and ritodrine clearance (y=-0.038x+2.75, r=0.349, p<0.001) among all patients. However, when analyzed on an individual basis, there was a high correlation found in three of the 14 patients. CONCLUSION: Due to a decrease in total body clearance in three of the 14 patients, overall serum concentration of ritodrine increased at the end of the pregnancies. To further characterize ritodrine kinetics, additional studies are needed to determine an effective and safe therapy for ritodrine use in twin pregnancy patients.
OBJECTIVES: To establish a rational ritodrine therapy in relation to serum ritodrine concentration, we examined 14 twin pregnancy patients and determined their pharmacokinetic data. METHODS: We measured serum concentrations of ritodrine in twin pregnancy patients using high-performance liquid chromatography (HPLC). RESULTS: The twin pregnancy patients all exhibited linear ritodrine pharmacokinetic profiles. There was a statistically significant but slight negative correlation between gestation period and ritodrine clearance (y=-0.038x+2.75, r=0.349, p<0.001) among all patients. However, when analyzed on an individual basis, there was a high correlation found in three of the 14 patients. CONCLUSION: Due to a decrease in total body clearance in three of the 14 patients, overall serum concentration of ritodrine increased at the end of the pregnancies. To further characterize ritodrine kinetics, additional studies are needed to determine an effective and safe therapy for ritodrine use in twin pregnancy patients.
Authors: Praveen Ballabh; E S Lo; J Kumari; T B Cooper; I Zervoudakis; P A M Auld; A N Krauss Journal: Clin Pharmacol Ther Date: 2002-01 Impact factor: 6.875